Contents
BAT Testing and BATCheck
Quantifying brain clearance with plasma biomarkers
BAT Testing and BATCheck work together to measure and interpret clearance efficiency, the brain’s ability to regulate and clear Beta-Amyloid (Aβ) and Tau (T) proteins. BAT Testing focuses on validated plasma assays, Aβ42/40, pTau-181, pTau-217. BATCheck adds upstream context, inflammation, metabolic state, circadian alignment, to identify drivers of biological drift.
Why this matters
Traditional methods detect change after symptoms. This framework supports preventive action by tracking clearance rhythm early, in a real-world, repeatable way. The intent is educational and observational, not diagnostic or treatment-oriented.
How the system fits together
| Component | What it does | Public-health role |
|---|---|---|
| BAT Testing | Measures Aβ42/40 and pTau (181 or 217) via CLIA-certified labs | Establishes clearance baseline and trend |
| BATCheck | Evaluates inflammation, metabolic friction, circadian alignment | Flags upstream influences on drift |
| BATScore | Converts longitudinal data into a single index | Enables population-level tracking |
| BATReset | Short cycle to re-stabilize clearance rhythm under clinician oversight | Supports maintenance, not disease modification |
| BATWatch Registry | Aggregates de-identified lab and context data | Real-world evidence for quantitative prevention |
Key points
- Uses plasma biomarkers with growing validation in large research cohorts.
- Adds upstream context to explain change, not just measure it.
- Designed for repeated monitoring, population analysis, and neutral reporting.
- Frames outcomes as observational and exploratory, consistent with public-health goals.
Alignment
The approach aligns with WHO dementia prevention priorities, CDC Healthy Brain Initiative, and NIH translational goals for scalable biomarkers.
Reference:
BATWatch Research Group (2025). Quantifying Brain Clearance Through BAT Testing and BATChecks. Zenodo. http://doi.org/10.5281/zenodo.17524148
